Arteris Announces Financial Results for the Third Quarter and Estimated Fourth Quarter and Updated Full Year 2026 Guidance
An at-the-market common-stock offering generated $72.037 million in net proceeds during the first nine months of 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arteris (Nasdaq: AIP) reported third-quarter 2026 revenue of $25.8 million, up 48% year over year, and updated its full-year outlook.
Annual contract value plus royalties reached $103.8 million, up 39%, while remaining performance obligations—contracted revenue not yet recognized—rose 29% to $135.5 million. The operating loss widened to $11.316 million from $8.714 million a year earlier. Net loss reached $11.154 million, or $0.23 per share, versus $8.991 million, or $0.21 per share. The non-GAAP operating loss narrowed to $1.2 million from $3.5 million.
Arteris expects fourth-quarter revenue of $25.7–$26.7 million and non-GAAP operating results ranging from a $0.9 million loss to $1.1 million income. Full-year guidance calls for revenue of $98.5–$99.5 million, a non-GAAP operating loss of $7.2–$9.2 million and free cash flow of $5.0–$9.0 million. License agreements included a top US hyperscaler and an automotive OEM.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 revenue rose 48% year over year to $25.8 million.
- Moderate pointAnnual contract value plus royalties increased 39% year over year to $103.8 million.
- Moderate pointRemaining performance obligations, contracted revenue not yet recognized, increased 29% year over year to $135.5 million.
- Moderate pointQ3 gross profit increased to $22.323 million from $15.642 million a year earlier.
- Moderate pointNon-GAAP Q3 operating loss narrowed to $1.2 million from $3.5 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Q4 revenue guidance is $25.7–$26.7 million; Arteris expects non-GAAP operating results of $(0.9)–$1.1 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year revenue guidance is $98.5–$99.5 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Year-end annual contract value plus royalties guidance is $103.0–$107.0 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year free cash flow guidance is $5.0–$9.0 million.
- Moderate pointAt-the-market common-stock offering generated $72.037 million net of commissions and offering costs during the first nine months. 8.1% of market cap
8 minor points
- Minor pointTrailing-twelve-month variable royalties increased 71% year over year to $9.4 million.
- Minor pointLicense agreements expanded existing use by a top US hyperscaler and two semiconductor companies.
- Minor pointAutomotive OEM license agreement expanded technology use across successive generations of in-house chip designs.
- Minor pointConfirmed design starts surpassed 1,000 since inception.
- Minor pointNine-month revenue increased to $72.844 million from $50.442 million a year earlier.
- Minor pointCash and cash equivalents rose to $71.014 million at September 30 from $33.901 million at December 31, 2025.
- Minor pointShort-term investments rose to $33.169 million at September 30 from $20.698 million at December 31, 2025.
- Minor pointStockholders’ equity reached $65.864 million at September 30, versus a $14.632 million deficit at December 31, 2025.
Negative
- Moderate pointQ3 operating loss widened to $11.316 million from $8.714 million a year earlier.
- Moderate pointQ3 net loss widened to $11.154 million, or $0.23 per share, from $8.991 million, or $0.21.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year non-GAAP operating loss guidance is $7.2–$9.2 million.
- Moderate pointNine-month operating cash flow fell to $0.397 million from $3.563 million a year earlier.
- Moderate pointNine-month business-combination payments totaled $11.179 million, net of acquired cash. 1.3% of market cap
- Moderate pointCommon shares outstanding increased to 49,657,293 at September 30 from 44,268,816 at December 31, 2025, diluting holders.
9 minor points
- Minor pointNon-GAAP Q3 net loss was $1.1 million, or $0.02 per share.
- Minor pointNine-month net loss widened to $33.178 million from $26.242 million a year earlier.
- Minor pointQ3 research and development expense rose to $16.434 million from $12.648 million a year earlier.
- Minor pointQ3 sales and marketing expense rose to $9.787 million from $6.850 million a year earlier.
- Minor pointQ3 general and administrative expense rose to $7.297 million from $4.858 million a year earlier.
- Minor pointAcquisition-related costs totaled $0.121 million in Q3 and $2.920 million during the first nine months.
- Minor pointNine-month stock-based compensation rose to $21.044 million from $13.765 million a year earlier.
- Minor pointCurrent vendor financing obligations rose to $2.031 million at September 30 from $1.166 million at December 31, 2025.
- Minor pointNoncurrent vendor financing obligations rose to $2.256 million at September 30 from $0.452 million at December 31, 2025.
News Explained
In the first nine months of 2026, Arteris received
Details
Market Reaction – AIP
On Nov 5, the day this news came out, the latest delayed price for AIP is 2.20% above the previous close. Our momentum scanner has recorded 41 alerts for this stock so far that day. The latest delayed price is $16.28. Relative volume is elevated at 2.0x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $25.8 million; up 48% year-over-year
- Q3 2026
- ACV plus royalties
- $103.8 million; up 39% year-over-year
- Q3 2026; record result
- Variable royalties
- $9.4 million; up 71% year-over-year
- Trailing twelve months
- Remaining performance obligation
- $135.5 million; up 29% year-over-year
- Q3 2026
- Operating loss
- $11.3 million
- Q3 2026; versus $8.7 million in Q3 2025
- Q4 revenue guidance
- $25.7–$26.7 million
- Q4 2026; prior estimate was $24.0–$25.0 million
- Full-year revenue guidance
- $98.5–$99.5 million
- FY 2026; prior range was $95.0–$98.0 million
- Free cash flow guidance
- $5.0–$9.0 million
- FY 2026
Previous Earnings Reports
-
Q2 revenue rose 46%, ACV plus royalties reached $99.5M, and FY revenue guidance was $95–$98M.
-
Q1 revenue and ACV plus royalties each grew 39%; full-year revenue guidance stood at $91–$95M.
-
Q3 revenue reached $17.4M, up 18%, with ACV plus royalties at $74.9M, up 24%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
remaining performance obligation financial
at-the-market offering financial
network-on-chip technical
system-on-chip technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMPBELL, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the third quarter ended September 30, 2026 and provided estimated fourth quarter and updated full year 2026 guidance.
“In the third quarter, Arteris delivered another set of record results, including Annual Contract Value plus royalties of
Third Quarter 2026 Financial Highlights:
- Revenue of
$25.8 million , up48% year-over-year - Trailing-twelve-months variable royalties of
$9.4 million , up71% year-over-year - Annual Contract Value (ACV) plus royalties of
$103.8 million , up39% year-over-year - Remaining Performance Obligation (RPO) of
$135.5 million , up29% year-over-year - Operating loss of
$11.3 million , compared to an operating loss of$8.7 million in the third quarter of 2025 - Non-GAAP operating loss of
$1.2 million , compared to a Non-GAAP operating loss of$3.5 million in the third quarter of 2025 - Net loss of
$11.2 million or$0.23 per share - Non-GAAP net loss of
$1.1 million or$0.02 per share
Third Quarter 2026 Business Highlights:
- Strong license activity in the third quarter, supported by integration of data center, edge, and physical AI computing across all market verticals. Increases in customers shifting to multi-product orders, supporting the ever-growing complexity of semiconductor innovation;
- Surpassed 1,000 confirmed design starts since inception. Arteris has supported innovation from the smartphone inflection to today’s deployments in sophisticated infrastructure AI, intelligent edge devices, and physical AI;
- Expanded our chiplet and multi-die solution. FlexGen Multi-Die and Ncore Multi-Die products support chiplet architectures for agentic AI workflows, HPC, data center, cloud infrastructure, physical AI, and more;
- Major license deals with a top US hyperscaler and two market-leading semiconductor companies, expanding their existing use of Arteris technology to accelerate development of chips and chiplets;
- Major license deal with a leading automotive OEM, expanding its use of Arteris technology for successive generations of their in-house advanced chip designs; and
- Announced the expansion of semiconductor cybersecurity third-party IP security assurance through the Trusted and Assured Microelectronics program, in collaboration with BAE Systems and SiFive.
Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP operating loss, Non-GAAP net loss, Non-GAAP net loss per share, and free cash flow are Non-GAAP financial measures. Additional information on Arteris’ historic reported results, including a reconciliation of these Non-GAAP financial measures to their most comparable GAAP measures, is included in the financial tables below.
Estimated Fourth Quarter and Updated Full Year 2026 Guidance:
| Q4 2026 | FY 2026 | |
| (in millions) | ||
| ACV + royalties | ||
| Revenue | ||
| Non-GAAP operating (loss) income | ||
| Free cash flow | * | |
*As previously mentioned during the first quarter 2026 earnings call, we no longer provide quarterly free cash flow guidance.
The guidance provided above are forward-looking statements and reflects Arteris' expectations as of today's date. Actual results may differ materially. Refer to the section titled "Forward-Looking Statements" below for information on the factors, among others, that could cause our actual results to differ materially from these forward-looking statements.
A reconciliation of Non-GAAP guidance measures reported above to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Arteris' results computed in accordance with GAAP.
Definitions of the other business metrics used in this press release including ACV, confirmed design starts and RPO are included below under the heading “Other Business Metrics.”
Conference Call
Arteris will host a conference call today on November 5, 2026 to review its third quarter 2026 financial results and to discuss its financial outlook.
| Time: | 4:30PM ET | |
| United States/Canada Toll Free: | 1-800-717-1738 | |
| International Toll: | 1-646-307-1865 | |
A live webcast will also be available in the Investor Relations section of Arteris’ website at: https://ir.arteris.com/events-and-presentations
A replay of the webcast will be available in the Investor Relations section of Arteris' website approximately two hours after the conclusion of the call and remain available for approximately 30 calendar days.
About Arteris
Arteris is a leading provider of semiconductor technology that accelerates the creation of high-performance, power-efficient silicon with built-in safety, reliability, and security. Innovative Arteris products are designed to optimize data movement and help ease complexity in the modern AI era with network-on-chip (NoC) interconnect intellectual property (IP), system-on-chip (SoC) software for integration automation and hardware security assurance. All are used by the world’s top technology companies to improve overall performance and engineering productivity, reduce risk, lower costs, and bring cutting-edge designs to market faster. Learn more at arteris.com.
© 2004-2026 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.
Investor Contacts:
Arteris
Saurabh Sinha
Chief Financial Officer
IR@arteris.com
Sapphire Investor Relations, LLC
Erica Mannion and Michael Funari
+1 617 542 6180
IR@arteris.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to, statements regarding market trends and whether we are well positioned to serve our customers accelerate innovation and bring their next-generation products to market, our long-term growth opportunity and future financial and operating performance, including our GAAP and Non-GAAP estimated fourth quarter and updated full year 2026 guidance. The words such as "may," "will," "could," "should", "anticipate", "plan", "intend", "continue", "expect," "approximately," "believe," "estimate," "future," "guidance," "outlook," and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained herein are based on our historical performance and our current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent our expectations as of the date of this press release. Subsequent events may cause these expectations to change, and we disclaim any obligation to update the forward-looking statements in the future, except as required by law. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from our current expectations. Important factors that could cause actual results to differ materially from those anticipated in our forward-looking statements include, but are not limited to, the significant competition we face from larger companies and third-party providers; our history of net losses; the amount of our future revenue recognition as it relates to our RPO as of September 30, 2026; whether semiconductor companies in the aerospace and defense market, automotive market, communications market, consumer electronics market, enterprise computing market, and industrial market incorporate our solutions into their end products and the growth and economic stability of these end markets; demand for, and the pace of adoption of, AI computing and chiplet and multi-die architectures, including our FlexGen Multi-Die and Ncore Multi-Die products; our ability to attract new customers and the extent to which our customers renew their subscriptions for our solutions; the ability of our customers’ end products achieving market acceptance or growth; our ability to sustain or grow our licensing revenue; our ability, and the cost, to successfully execute on research and development efforts; the occurrence of product errors or defects in our solutions; if we fail to offer high-quality support; the occurrence of macro-economic conditions that adversely impact us, our customers and their end product markets including, but not limited to, the imposition of tariffs in markets where we operate; the effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine as well as the conflicts in the Middle East; the range of regulatory, operational, financial and political risks we are exposed to as a result of our dependence on international customers and operations; our ability to protect our proprietary technology and inventions through patents and other IP rights; whether we are subject to any liabilities or fines as a result of government regulation, including import, export and economic sanctions laws and regulations; the occurrence of a disruption in our networks or a security breach; risks associated with doing business in China, including as a result of changes to trade relations between the United States and China; and the other factors described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the Securities and Exchange Commission (SEC) on November 5, 2026. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. Our results for the quarter ended September 30, 2026 are not necessarily indicative of our operating results for any future periods.
Arteris, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | |||||||||||||||
| Licensing, support and maintenance | $ | 22,368 | $ | 15,896 | $ | 62,464 | $ | 46,319 | |||||||
| Variable royalties | 2,294 | 1,505 | 6,900 | 4,074 | |||||||||||
| Professional services and other | 1,112 | 7 | 3,480 | 49 | |||||||||||
| Total revenue | 25,774 | 17,408 | 72,844 | 50,442 | |||||||||||
| Cost of revenue | 3,451 | 1,766 | 10,308 | 5,034 | |||||||||||
| Gross profit | 22,323 | 15,642 | 62,536 | 45,408 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 16,434 | 12,648 | 47,653 | 36,681 | |||||||||||
| Sales and marketing | 9,787 | 6,850 | 27,703 | 19,714 | |||||||||||
| General and administrative | 7,297 | 4,858 | 18,784 | 13,683 | |||||||||||
| Acquisition-related costs | 121 | — | 2,920 | — | |||||||||||
| Total operating expenses | 33,639 | 24,356 | 97,060 | 70,078 | |||||||||||
| Loss from operations | (11,316 | ) | (8,714 | ) | (34,524 | ) | (24,670 | ) | |||||||
| Interest expense | (85 | ) | (49 | ) | (153 | ) | (139 | ) | |||||||
| Other income (expense), net | 1,092 | 636 | 2,332 | 2,140 | |||||||||||
| Loss before income taxes and loss from equity method investment | (10,309 | ) | (8,127 | ) | (32,345 | ) | (22,669 | ) | |||||||
| Loss from equity method investment, net of tax | — | 484 | 2,989 | 2,079 | |||||||||||
| Loss before income taxes | (10,309 | ) | (8,611 | ) | (35,334 | ) | (24,748 | ) | |||||||
| Provision for (benefit from) income taxes | 845 | 380 | (2,156 | ) | 1,494 | ||||||||||
| Net loss | $ | (11,154 | ) | $ | (8,991 | ) | $ | (33,178 | ) | $ | (26,242 | ) | |||
| Net loss per share attributable to common stockholders, basic | $ | (0.23 | ) | $ | (0.21 | ) | $ | (0.70 | ) | $ | (0.63 | ) | |||
| Weighted-average shares used in computing per share amounts, basic and diluted | 49,384,114 | 42,743,518 | 47,415,840 | 41,812,256 | |||||||||||
Arteris, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
| As of | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 71,014 | $ | 33,901 | |||
| Short-term investments | 33,169 | 20,698 | |||||
| Accounts receivable, net of allowance of | 20,959 | 19,183 | |||||
| Prepaid expenses and other current assets | 9,036 | 8,608 | |||||
| Total current assets | 134,178 | 82,390 | |||||
| Property and equipment, net | 6,946 | 3,872 | |||||
| Long-term investments | 16,114 | 4,946 | |||||
| Equity method investment | — | 2,989 | |||||
| Operating lease right-of-use assets | 4,634 | 3,919 | |||||
| Intangibles, net | 17,986 | 2,168 | |||||
| Goodwill | 35,156 | 4,178 | |||||
| Other assets | 12,917 | 10,569 | |||||
| TOTAL ASSETS | $ | 227,931 | $ | 115,031 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,490 | $ | 340 | |||
| Accrued expenses and other current liabilities | 31,187 | 19,094 | |||||
| Operating lease liabilities, current | 1,501 | 1,233 | |||||
| Deferred revenue, current | 63,524 | 51,367 | |||||
| Vendor financing arrangements, current | 2,031 | 1,166 | |||||
| Total current liabilities | 99,733 | 73,200 | |||||
| Deferred revenue, noncurrent | 48,527 | 43,974 | |||||
| Operating lease liabilities, noncurrent | 3,386 | 3,116 | |||||
| Vendor financing arrangements, noncurrent | 2,256 | 452 | |||||
| Deferred income, noncurrent | 5,570 | 6,452 | |||||
| Other liabilities | 2,595 | 2,469 | |||||
| Total liabilities | 162,067 | 129,663 | |||||
| Stockholders' equity (deficit): | |||||||
| Preferred stock, par value of | — | — | |||||
| Common stock, par value of | 49 | 44 | |||||
| Additional paid-in capital | 270,569 | 156,776 | |||||
| Accumulated other comprehensive income | 55 | 179 | |||||
| Accumulated deficit | (204,809 | ) | (171,631 | ) | |||
| Total stockholders' equity (deficit) | 65,864 | (14,632 | ) | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 227,931 | $ | 115,031 | |||
Arteris, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Nine Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
| Net loss | $ | (33,178 | ) | $ | (26,242 | ) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 4,333 | 2,532 | |||||
| Stock-based compensation | 21,044 | 13,765 | |||||
| Amortization of deferred income | (882 | ) | (882 | ) | |||
| Loss from equity method investment | 2,989 | 2,079 | |||||
| Deferred income taxes | (4,103 | ) | — | ||||
| Net accretion of discounts on available-for-sale securities | (105 | ) | (306 | ) | |||
| Change in fair value of contingent consideration liability | 2,058 | — | |||||
| Other, net | 47 | 390 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | (360 | ) | 4,128 | ||||
| Prepaid expenses and other assets | (3,085 | ) | (3,740 | ) | |||
| Accounts payable | 116 | (77 | ) | ||||
| Accrued expenses and other liabilities | (1,727 | ) | 1,666 | ||||
| Deferred revenue | 13,250 | 10,250 | |||||
| Net cash provided by operating activities | 397 | 3,563 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
| Purchases of property and equipment | (1,265 | ) | (1,254 | ) | |||
| Purchases of available-for-sale securities | (44,223 | ) | (25,308 | ) | |||
| Proceeds from maturities of available-for-sale securities | 20,465 | 25,515 | |||||
| Payments for business combination, net of cash acquired | (11,179 | ) | — | ||||
| Net cash used in investing activities | (36,202 | ) | (1,047 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
| Principal payments under vendor financing arrangements | (1,100 | ) | (882 | ) | |||
| Proceeds from exercise of stock options | 1,241 | 1,523 | |||||
| Proceeds from employee stock purchase plan | 644 | 535 | |||||
| Proceeds from issuance of common stock under the at-the-market offering, net of commissions and offering costs | 72,037 | — | |||||
| Other financing activities | 93 | 99 | |||||
| Net cash provided by financing activities | 72,915 | 1,275 | |||||
| NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 37,110 | 3,791 | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 34,250 | 14,072 | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period | $ | 71,360 | $ | 17,863 | |||
Non-GAAP Financial Measures
To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors’ overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We define "Non-GAAP gross profit" and "Non-GAAP gross margin" as GAAP gross profit and GAAP gross margin, respectively, adjusted for stock-based compensation expense included in cost of revenue and amortization of acquired intangible assets included in cost of revenue. We define “Non-GAAP loss from operations” as our GAAP loss from operations adjusted to exclude stock-based compensation expense, amortization of acquired intangible assets and acquisition-related costs, which include advisory, legal, accounting, valuation, other professional or consulting fees, integration costs and changes in the fair value of the contingent consideration related to our acquisition of Cycuity. We define “Non-GAAP net loss” as our net loss adjusted to exclude stock-based compensation, amortization of acquired intangible assets and acquisition-related costs.
We define “Non-GAAP net loss per share attributable to common stockholders, basic and diluted”, as our Non-GAAP net loss divided by our GAAP weighted-average number of shares outstanding for the period on a basic or diluted basis, respectively. Management uses this non-GAAP measure to evaluate the performance of our business on a comparable basis from period to period.
The above items are excluded from our Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance.
We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash provided by (used in) our operations other than that used for investments in property and equipment.
Other Business Metrics
Annual Contract Value (ACV) – we define Annual Contract Value for an individual customer agreement as the total fixed fees under the agreement divided by the number of years in the agreement term. Our total ACV is the aggregate ACVs for all our customers as measured at a given point in time. Total fixed fees includes licensing, support and maintenance and other fixed fees under IP licensing or software licensing agreements but excludes variable revenue derived from licensing agreements with customers, particularly royalties. We define ACV plus royalties as ACV plus the trailing-twelve-months variable royalties and other revenue.
Confirmed Design Starts – we define Confirmed Design Starts as when customers confirm their commencement of new semiconductor designs using our interconnect IP and notify us. Confirmed Design Starts is a metric management uses to assess the activity level of our customers in terms of the number of new semiconductor designs that are started using our interconnect IP in a given period. We believe that the number of Confirmed Design Starts is an important indicator of the growth of our business and future royalty revenue trends.
Remaining Performance Obligations (RPO) – we define Remaining Performance Obligations as the amount of contracted future revenue that has not yet been recognized, including deferred revenue, billed and unbilled cancelable and non-cancelable contracted amounts.
Arteris, Inc.
Reconciliation of GAAP Measures to Non-GAAP Measures
(In thousands)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Gross profit | $ | 22,323 | $ | 15,642 | $ | 62,536 | $ | 45,408 | |||||||
| Add: | |||||||||||||||
| Stock-based compensation expense included in cost of revenue | 442 | 228 | 1,147 | 665 | |||||||||||
| Amortization of acquired intangible assets (1) | 50 | 50 | 150 | 150 | |||||||||||
| Non-GAAP gross profit | $ | 22,815 | $ | 15,920 | $ | 63,833 | $ | 46,223 | |||||||
| Gross margin | 87 | % | 90 | % | 86 | % | 90 | % | |||||||
| Non-GAAP gross margin | 89 | % | 91 | % | 88 | % | 92 | % | |||||||
| Research and development | $ | 16,434 | $ | 12,648 | $ | 47,653 | $ | 36,681 | |||||||
| Stock-based compensation expense | (3,550 | ) | (2,095 | ) | (8,368 | ) | (5,994 | ) | |||||||
| Amortization of acquired intangible assets (1) | (367 | ) | (110 | ) | (1,054 | ) | (330 | ) | |||||||
| Non-GAAP research and development | $ | 12,517 | $ | 10,443 | $ | 38,231 | $ | 30,357 | |||||||
| Sales and marketing | $ | 9,787 | $ | 6,850 | $ | 27,703 | $ | 19,714 | |||||||
| Stock-based compensation expense | (1,916 | ) | (1,335 | ) | (4,967 | ) | (3,352 | ) | |||||||
| Amortization of acquired intangible assets (1) | (359 | ) | (57 | ) | (1,035 | ) | (171 | ) | |||||||
| Non-GAAP sales and marketing | $ | 7,512 | $ | 5,458 | $ | 21,701 | $ | 16,191 | |||||||
| General and administrative | $ | 7,297 | $ | 4,858 | $ | 18,784 | $ | 13,683 | |||||||
| Stock-based compensation expense | (3,278 | ) | (1,298 | ) | (6,562 | ) | (3,754 | ) | |||||||
| Non-GAAP general and administrative | $ | 4,019 | $ | 3,560 | $ | 12,222 | $ | 9,929 | |||||||
| Acquisition-related costs | $ | 121 | $ | — | $ | 2,920 | $ | — | |||||||
| Acquisition-related costs (2) | (121 | ) | — | (2,920 | ) | — | |||||||||
| Non-GAAP acquisition-related costs | $ | — | $ | — | $ | — | $ | — | |||||||
| Total operating expenses | $ | 33,639 | $ | 24,356 | $ | 97,060 | $ | 70,078 | |||||||
| Stock-based compensation expense | (8,744 | ) | (4,728 | ) | (19,897 | ) | (13,100 | ) | |||||||
| Amortization of acquired intangible assets (1) | (726 | ) | (167 | ) | (2,089 | ) | (501 | ) | |||||||
| Acquisition-related costs (2) | (121 | ) | — | (2,920 | ) | — | |||||||||
| Total Non-GAAP operating expenses | $ | 24,048 | $ | 19,461 | $ | 72,154 | $ | 56,477 | |||||||
| Loss from operations | $ | (11,316 | ) | $ | (8,714 | ) | $ | (34,524 | ) | $ | (24,670 | ) | |||
| Stock-based compensation expense | 9,186 | 4,956 | 21,044 | 13,765 | |||||||||||
| Amortization of acquired intangible assets (1) | 776 | 217 | 2,239 | 651 | |||||||||||
| Acquisition-related costs (2) | 121 | — | 2,920 | — | |||||||||||
| Non-GAAP loss from operations | $ | (1,233 | ) | $ | (3,541 | ) | $ | (8,321 | ) | $ | (10,254 | ) | |||
| Net loss | $ | (11,154 | ) | $ | (8,991 | ) | $ | (33,178 | ) | $ | (26,242 | ) | |||
| Stock-based compensation expense | 9,186 | 4,956 | 21,044 | 13,765 | |||||||||||
| Amortization of acquired intangible assets (1) | 776 | 217 | 2,239 | 651 | |||||||||||
| Acquisition-related costs (2) | 121 | — | 2,920 | — | |||||||||||
| Non-GAAP net loss (3) | $ | (1,071 | ) | $ | (3,818 | ) | $ | (6,975 | ) | $ | (11,826 | ) | |||
(1) Represents the amortization expenses of our intangible assets attributable to our acquisitions.
(2) Includes advisory, legal, accounting, valuation, other professional or consulting fees and integration costs associated with the Cycuity acquisition. Acquisition-related costs also include change in the fair value of the contingent consideration related to our acquisition of Cycuity.
(3) Our GAAP tax provision is primarily related to foreign withholding taxes and income tax in profitable foreign jurisdictions. We maintain a full valuation allowance against our deferred tax assets in the US. Accordingly, there is no significant tax impact associated with these Non-GAAP adjustments.
Arteris, Inc.
Reconciliation of GAAP Measures to Non-GAAP Measures
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.23 | ) | $ | (0.21 | ) | $ | (0.70 | ) | $ | (0.63 | ) | |||
| Per share impacts of adjustments to net loss (1) | $ | 0.21 | $ | 0.12 | $ | 0.55 | $ | 0.35 | |||||||
| Non-GAAP net loss per share attributable to common stockholders, basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.15 | ) | $ | (0.28 | ) | |||
| Weighted-average shares used in computing per share amounts, basic and diluted | 49,384,114 | 42,743,518 | 47,415,840 | 41,812,256 | |||||||||||
(1) Reflects the aggregate adjustments made to reconcile Non-GAAP net loss to our net loss as noted in the above table, divided by the GAAP diluted weighted average number of shares of the relevant period.
Free Cash Flow
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (in thousands) | |||||||||||||||
| Net cash (used in) provided by operating activities | $ | (1,751 | ) | $ | 3,187 | $ | 397 | $ | 3,563 | ||||||
| Less: | |||||||||||||||
| Purchase of property and equipment | (375 | ) | (716 | ) | (1,265 | ) | (1,254 | ) | |||||||
| Free cash flow | $ | (2,126 | ) | $ | 2,471 | $ | (868 | ) | $ | 2,309 | |||||
| Net cash used in investing activities | $ | (19,782 | ) | $ | (1,631 | ) | $ | (36,202 | ) | $ | (1,047 | ) | |||
| Net cash (used in) provided by financing activities | $ | (724 | ) | $ | (180 | ) | $ | 72,915 | $ | 1,275 | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.